Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe.

The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane

Criteria

Inclusion Criteria:

• Patients with Type 1 or Type 2 diabetes, including newly diagnosed

• Age: Levemir® above 6 years

• Age: Novomix® above 18 years

Exclusion Criteria:

• Current treatment with NovoMix® 30 or Levemir®